Nonfusion Alternative To Artificial Discs Acquired By Abbott/Spinal Concepts
This article was originally published in The Pink Sheet Daily
Abbott purchases Spine Next for $60 mil. plus milestone payments for commercializing the Wallis nonfusion spine stabilization device. Although Abbott touts Wallis as a less-invasive alternative to artificial discs for early degenerative disc disease, the firm plans a PMA submission for a disc of its own.
You may also be interested in...
Dependence on Boston Scientific's Taxus royaltieis will fall significantly once Angiotech offers AMI's oncology, aesthetic, wound closure and ophthalmology devices.
Allergan may be forced to divest more than Inamed's development-stage botulinum toxin type A product, Reloxin.
Justice Department is unlikely to investigate off-label drug claims unless a firm is also offering kickbacks or bilking Medicare or Medicaid, Laura Laemmle asserts, discussing recent case against drug firm Serono.